Review recaps ARA-290 preclinical work on innate repair receptor
The eleven-amino-acid EPO fragment, also called cibinetide, was designed to signal through the EPOR–CD131 complex without driving red blood cell production.
PR
By Priya Raman · Science Reporter
Oct 19 22:48 ETSource: Intelligent Living
The wire
- 01The piece reviews ARA-290, a synthetic 11-amino-acid peptide derived from the helix-B surface of EPO and described by Michael Brines and colleagues in a 2008 PNAS paper.
- 02Readers tracking repair peptides will note the design goal: engage the innate repair receptor, a heterodimer of EPOR and beta common receptor CD131, while omitting erythropoietic activity.
- 03The article is published by a research-peptide supplier context, cites only preclinical cell and animal work, and notes the compound is sold for laboratory use with no approval for human consumption.
From the source
Read at intelligentliving.coARA-290 Research Peptide: What Preclinical Work Shows in 2026
Erythropoietin, usually shortened to EPO, is best known as the hormone that drives red blood cell production. Researchers have also spent years examining a second, quieter role: in cell culture and animal models, EPO signaling has been linked to survival pathways in tissues far from the bone marrow. That finding created a design problem. A laboratory interested in the tissue-facing activity of EPO
